Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
Melanotan II nasal spray may pose serious risks, including the potential development of malignant melanoma, as evidenced by this case report.
Where it sits
this study against the rest of the melanotan ii corpusSummary and findings
This case report describes a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II nasal spray for tanning. Histological analysis confirmed a diagnosis of mucosal malignant melanoma, leading to surgical resection and ongoing immunotherapy. The report emphasizes the potential risks associated with Melanotan II use.
Abstract
The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. The patient had used the nasal spray for tanning purposes. Melanotan II is unlicensed, and its sale is illegal in the United Kingdom and in many other countries around the world. Histological analysis confirmed the diagnosis of a mucosal malignant melanoma. The patient subsequently underwent surgical resection followed by ongoing immunotherapy. The clinical presentation and initial management of the patient, along with a literature review on the potential association between Melanotan use and the development of malignant melanoma, is provided. This report highlights the need for awareness of the possible serious side effects associated with Melanotan II nasal spray.
Background
The paper addresses the concern of whether Melanotan II nasal spray could be a risk factor for developing oral mucosal malignant melanoma. Previous studies have indicated potential risks associated with Melanotan II, but the specific implications for oral mucosal health remain underexplored. This study aims to fill that gap by examining the relationship between Melanotan II use and melanoma incidence.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.